By Sara Fournier, Clinical Team Lead
A mid-sized biotech company was in the middle of conducting an open-label long-term safety study with 137 active patients across 25 sites in the US and Canada. Then the COVID-19 pandemic hit.
Facing clinical site closures and obstacles to patient availability due to the pandemic, they turned to Rho for help. Read how we developed a customized and decentralized solution for their study that would ensure patient safety and data quality while allowing their study to progress according to FDA guidelines for conducting research during this pandemic.